Propanc Biopharma, Inc. 是一家处于研发阶段的医疗保健公司,从事癌症治疗的研究与开发。该公司专注于为患有胰腺癌、卵巢癌和结直肠癌的患者开发新型癌症治疗方法。公司开发了一种合理复合的抗癌化合物配方,这些化合物共同发挥多种作用,旨在控制或防止肿瘤复发和在体内扩散。其主要产品候选药物PRP是该配方的一种变体,包含前酶——酶的非活性前体。PRP是一种基于胰腺前酶配方的长期疗法,用于防止肿瘤复发和转移。PRP是一种专利配方,由两种以前酶以协同比例混合组成。PRP目前处于临床前开发阶段。其药物研发管线还包括POP1。
PPCB stock price ended at $0.22 on 星期二, after rising 4.76%
On the latest trading day Feb 17, 2026, the stock price of PPCB rose by 4.76%, climbing from $0.24 to $0.22. Throughout the session, the stock experienced a volatility of 33.33%, with prices fluctuating between a daily low of $0.18 and a high of $0.24. Alongside this price increase, trading volume also rose by 407.9K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 1.1M shares were traded, amounting to a market value of approximately $2.9M.